RESTING METABOLIC-RATE, BODY-COMPOSITION AND RELATED HORMONAL PARAMETERS IN GROWTH HORMONE-DEFICIENT ADULTS BEFORE AND AFTER GROWTH-HORMONEREPLACEMENT THERAPY

Citation
Yem. Snel et al., RESTING METABOLIC-RATE, BODY-COMPOSITION AND RELATED HORMONAL PARAMETERS IN GROWTH HORMONE-DEFICIENT ADULTS BEFORE AND AFTER GROWTH-HORMONEREPLACEMENT THERAPY, European journal of endocrinology, 133(4), 1995, pp. 445-450
Citations number
24
Categorie Soggetti
Endocrynology & Metabolism
ISSN journal
08044643
Volume
133
Issue
4
Year of publication
1995
Pages
445 - 450
Database
ISI
SICI code
0804-4643(1995)133:4<445:RMBARH>2.0.ZU;2-M
Abstract
The resting metabolic rate (RMR), and body composition were assessed i n 30 growth hormone-deficient (GHD) adults before and after 3 and 6 mo nths of replacement therapy with recombinant human growth hormone (rhG H). In addition, insulin-like growth factor I (IGF-I), IGF binding pro teins (IGFBPs) and plasma insulin were measured at baseline and at 6 m onths in relation to RMR. During 6 months of rhGH replacement therapy, body fat decreased from 18.2 +/- 1.5 (mean +/- SEM to 14.3 +/- 1.6 kg (p < 0.0001), whereas fat-free mass (FFM) increased from 53.5 +/- 3.3 to 56.3 +/- 3-6 kg (p < 0.0001), RMR increased from 1246 +/- 92 to 15 39 +/- 102 kcal/24 h (p < 0.0001) and RMR per kilogram of FFM increase d from 23.2 +/- 0.6 to 27.4 +/- 0.5 (p < 0.0001). When RMR data were a djusted for the differences in FFM, it appeared that apart from the in crease in FFM, other factors may play a role in the increase in RMR. D uring rhGH replacement therapy, IGF-I (p < 0.0001) and IGFBP-3 (p = 0. 003) levels increased, whereas IGFBP-1 levels decreased significantly (p = 0.004). The FFM explained for about 80% of the variance in RMR. I n addition, waist/hip ratio and plasma IGF-I contributed significantly to the explained variance of RMR. This study shows that in GHD adults FFM is the main determinant of RMR and that, next to the increase in FFM, changes in metabolic and hormonal parameters contribute to the in crease in RMR during rhGH replacement therapy.